1. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏
by Peter Paschka, Juan Du, Richard F. Schlenk, Verena I. Gaidzik, Lars Bullinger, Andrea Corbacioglu, Daniela Späth, Sabine Kayser, Brigitte Schlegelberger, Jürgen Krauter, Arnold Ganser, Claus-Henning Köhne, Gerhard Held, Marie von Lilienfeld-Toal, Heinz Kirchen, Mathias Rummel, Katharina Götze, Heinz-August Horst, Mark Ringhoffer, Michael Lübbert, Mohammed Wattad, Helmut R. Salih, Andrea Kündgen, Hartmut Döhner, and Konstanze Döhner
Blood
Volume 121(1):
January 3, 2013
©2013 by American Society of Hematology

2. Pie chart illustrating the genetic heterogeneity and coexistence of the distinct secondary genetic abnormalities in AML with inv (16).
Pie chart illustrating the genetic heterogeneity and coexistence of the distinct secondary genetic abnormalities in AML with inv (16). The chart is based on 166 patients with complete cytogenetic data and complete mutation status on KIT, FLT3, NRAS, and KRAS. Among the secondary chromosome aberrations, trisomy 22 (+22) and trisomy 8 (+8) are indicated; all other secondary chromosome aberrations constitute 1 group abbreviated in the chart as “o.c.a.” Because of the rounding error, all values do not add up to exactly 100%.
Peter Paschka et al. Blood 2013;121:
©2013 by American Society of Hematology

3. Impact of trisomy 22 on RFS and OS. (A) RFS. (B) OS.
Peter Paschka et al. Blood 2013;121:
©2013 by American Society of Hematology

4. Impact of trisomy 8 on OS. Impact of trisomy 8 on OS.
Peter Paschka et al. Blood 2013;121:
©2013 by American Society of Hematology

5. Impact of KIT mutations on RFS.
Peter Paschka et al. Blood 2013;121:
©2013 by American Society of Hematology

6. Impact of FLT3 mutations on OS.
Peter Paschka et al. Blood 2013;121:
©2013 by American Society of Hematology